KR20120059572A - Ｔ－세포 도움을 유도하는 조성물 - Google Patents

Ｔ－세포 도움을 유도하는 조성물 Download PDF

Info

Publication number
KR20120059572A
KR20120059572A KR1020127007388A KR20127007388A KR20120059572A KR 20120059572 A KR20120059572 A KR 20120059572A KR 1020127007388 A KR1020127007388 A KR 1020127007388A KR 20127007388 A KR20127007388 A KR 20127007388A KR 20120059572 A KR20120059572 A KR 20120059572A
Authority
KR
South Korea
Prior art keywords
peptide
composition
binding peptide
identity
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127007388A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 프레이저
그레이슨 비. 립포드
로버트 라모트
데이비드 에이치. 알트레우터
Original Assignee
셀렉타 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀렉타 바이오사이언시즈, 인크. filed Critical 셀렉타 바이오사이언시즈, 인크.
Publication of KR20120059572A publication Critical patent/KR20120059572A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020127007388A 2009-08-26 2010-08-24 Ｔ－세포 도움을 유도하는 조성물 Ceased KR20120059572A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23714709P 2009-08-26 2009-08-26
US61/237,147 2009-08-26
US33561110P 2010-01-06 2010-01-06
US61/335,611 2010-01-06
PCT/US2010/002330 WO2011031298A1 (en) 2009-08-26 2010-08-24 Compositions that induce t cell help

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177017217A Division KR101873179B1 (ko) 2009-08-26 2010-08-24 Ｔ－세포 도움을 유도하는 조성물

Publications (1)

Publication Number Publication Date
KR20120059572A true KR20120059572A (ko) 2012-06-08

Family

ID=43732728

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177017217A Expired - Fee Related KR101873179B1 (ko) 2009-08-26 2010-08-24 Ｔ－세포 도움을 유도하는 조성물
KR1020127007388A Ceased KR20120059572A (ko) 2009-08-26 2010-08-24 Ｔ－세포 도움을 유도하는 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020177017217A Expired - Fee Related KR101873179B1 (ko) 2009-08-26 2010-08-24 Ｔ－세포 도움을 유도하는 조성물

Country Status (15)

Country Link
US (1) US20110110965A1 (enExample)
EP (2) EP3311833A3 (enExample)
JP (2) JP5933437B2 (enExample)
KR (2) KR101873179B1 (enExample)
CN (3) CN107715118A (enExample)
AU (2) AU2010293059B2 (enExample)
BR (1) BR112012003977A2 (enExample)
CA (1) CA2771863A1 (enExample)
EA (2) EA023897B1 (enExample)
ES (1) ES2641892T3 (enExample)
IL (2) IL218254A (enExample)
IN (1) IN2012DN02589A (enExample)
MX (1) MX343908B (enExample)
PL (1) PL2470554T3 (enExample)
WO (1) WO2011031298A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP3311833A3 (en) * 2009-08-26 2018-07-25 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2011150264A2 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
BR112013012195A2 (pt) * 2010-11-16 2018-07-10 Selecta Biosciences Inc oligonucleotídeo imunoestimulatórios
MX373641B (es) 2011-04-29 2020-05-04 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
KR20120132183A (ko) 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN105283175A (zh) 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
AU2015289583A1 (en) 2014-07-16 2017-02-02 Modernatx, Inc. Chimeric polynucleotides
KR20170045344A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
AU2016215604B2 (en) * 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
CA3028523A1 (en) * 2016-06-22 2017-12-28 Amsilk Gmbh Articles comprising a silk polypeptide for antigen delivery
JP7523909B2 (ja) 2017-03-11 2024-07-29 セレクタ バイオサイエンシーズ インコーポレーテッド 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
ES3004084T3 (en) 2017-04-22 2025-03-11 Immunomic Therapeutics Inc Improved lamp constructs
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
BR112020004149A2 (pt) * 2017-08-31 2020-09-08 Syngulon Sa métodos e composições para fabricar bacteriocinas e peptídeos antimicrobianos
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
BR112020020660A2 (pt) 2018-04-10 2021-03-02 Ac Immune Sa vacinas terapêuticas anti-abeta
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
TW202245835A (zh) * 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
US20250269010A1 (en) * 2021-02-05 2025-08-28 St Pharm Co., Ltd. Novel nucleic acid molecule

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5912017A (en) * 1987-05-01 1999-06-15 Massachusetts Institute Of Technology Multiwall polymeric microspheres
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
EP0671948B1 (en) * 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
CA2153391C (en) * 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
EP0922105B1 (en) * 1996-07-17 2005-12-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Infectious papillomavirus pseudoviral particles
AU730477B2 (en) * 1996-08-05 2001-03-08 President And Fellows Of Harvard College MHC binding peptide oligomers and methods of use
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
EP0938315B9 (en) 1996-10-25 2008-02-20 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
US6211159B1 (en) 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
PT1017721E (pt) * 1997-09-16 2009-05-07 Univ Oregon Health & Science Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
ES2205573T3 (es) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
US6254890B1 (en) * 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1388586A3 (en) * 1998-05-29 2004-05-26 Epimmune Inc. Identification of broadly reactive DR restricted epitopes
EP1080370A4 (en) * 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
US6306640B1 (en) * 1998-10-05 2001-10-23 Genzyme Corporation Melanoma antigenic peptides
PL202399B1 (pl) * 1998-10-05 2009-06-30 Pharmexa As Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an
DK1126876T3 (da) * 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6365179B1 (en) * 1999-04-23 2002-04-02 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7390780B2 (en) * 1999-04-23 2008-06-24 Alza Corporation Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification
US6800296B1 (en) * 1999-05-19 2004-10-05 Massachusetts Institute Of Technology Modification of surfaces using biological recognition events
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US6632671B2 (en) 2000-02-28 2003-10-14 Genesegues, Inc. Nanoparticle encapsulation system and method
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
CA2407897A1 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7192725B2 (en) 2000-05-19 2007-03-20 University Of Toronto Flagellin gene, flaC of Campylobacter
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040230380A1 (en) * 2002-01-04 2004-11-18 Xencor Novel proteins with altered immunogenicity
ES2734652T3 (es) 2002-04-04 2019-12-11 Zoetis Belgium S A Oligorribonucleótidos inmunoestimulantes que contienen G y U
FR2840499B1 (fr) * 2002-05-30 2004-12-10 Cit Alcatel Procede et dispositif de controle d'acces a un reseau local de communications sans fil
US20060189554A1 (en) * 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
EP1569515A4 (en) * 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
JP4509999B2 (ja) * 2003-02-17 2010-07-21 ブルクハルト，ペーター 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
WO2005011571A2 (en) * 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US20050137156A1 (en) * 2003-08-09 2005-06-23 Johnston Stephen A. Methods and compositions for generating an immune response
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
CA2549341C (en) 2003-12-19 2014-06-10 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
TW200533750A (en) 2004-02-19 2005-10-16 Coley Pharm Group Inc Immunostimulatory viral RNA oligonucleotides
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
WO2006014579A2 (en) * 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US9079765B2 (en) * 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
WO2006042333A2 (en) * 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US8404244B2 (en) * 2005-02-01 2013-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
AU2006279612B2 (en) * 2005-08-15 2013-03-21 Altimmune Inc. Immunization of avians by administration of non-replicating vectored vaccines
BRPI0622298A8 (pt) 2005-11-25 2016-04-05 Coley Pharm Gmbh Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
WO2007092182A2 (en) * 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
US8367113B2 (en) * 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
WO2008036981A1 (en) * 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
CN101678090B (zh) * 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CA3016942C (en) * 2007-05-31 2022-09-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
EP2187961A2 (en) * 2007-08-21 2010-05-26 Dynavax Technologies Corporation Composition and methods of making and using influenza proteins
CA2917512C (en) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
AU2009221419B2 (en) * 2008-02-01 2013-09-26 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
EP2244733B1 (en) * 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2250189A4 (en) * 2008-02-26 2012-07-04 Univ California GYLCOPEPTIDES AND METHOD FOR THEIR PREPARATION AND USE
US20110223201A1 (en) * 2009-04-21 2011-09-15 Selecta Biosciences, Inc. Immunonanotherapeutics Providing a Th1-Biased Response
WO2010138193A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP3311833A3 (en) * 2009-08-26 2018-07-25 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2011085231A2 (en) * 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
US20110262491A1 (en) * 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
WO2011150264A2 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
WO2012024629A1 (en) * 2010-08-20 2012-02-23 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
AU2011293508A1 (en) * 2010-08-23 2013-01-24 Selecta Biosciences, Inc. Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2012061717A1 (en) * 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US20120171229A1 (en) * 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
CA2830948A1 (en) * 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
MX373641B (es) * 2011-04-29 2020-05-04 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
CA2843274A1 (en) * 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
US20130058970A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines

Also Published As

Publication number Publication date
AU2010293059A1 (en) 2012-03-08
KR101873179B1 (ko) 2018-06-29
JP5933437B2 (ja) 2016-06-08
JP2016121149A (ja) 2016-07-07
CN107715118A (zh) 2018-02-23
IL218254A0 (en) 2012-04-30
WO2011031298A1 (en) 2011-03-17
EP3311833A2 (en) 2018-04-25
EA023897B1 (ru) 2016-07-29
BR112012003977A2 (pt) 2017-06-06
EA201270313A1 (ru) 2012-09-28
IL218254A (en) 2017-11-30
CN102574891A (zh) 2012-07-11
CN107617110A (zh) 2018-01-23
AU2010293059B2 (en) 2017-03-16
KR20170076804A (ko) 2017-07-04
MX2012002357A (es) 2012-04-10
US20110110965A1 (en) 2011-05-12
EP2470554A4 (en) 2014-05-07
EP3311833A3 (en) 2018-07-25
PL2470554T3 (pl) 2018-02-28
CA2771863A1 (en) 2011-03-17
JP2013503159A (ja) 2013-01-31
IL255009A0 (en) 2017-12-31
EP2470554B1 (en) 2017-06-28
EP2470554A1 (en) 2012-07-04
ES2641892T3 (es) 2017-11-14
EA201592264A1 (ru) 2016-08-31
MX343908B (es) 2016-11-28
IN2012DN02589A (enExample) 2015-08-28
AU2017201438A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
KR101873179B1 (ko) Ｔ－세포 도움을 유도하는 조성물
KR20130098308A (ko) 항원에 대한 면역 반응을 유도하기 위한 표적화 다중 에피토프 투여형
JP6324067B2 (ja) 多価合成ナノキャリアワクチン
Heit et al. Antigen co‐encapsulated with adjuvants efficiently drive protective T cell immunity
US20120058153A1 (en) Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
WO2011085231A2 (en) Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150824

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160720

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170126

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160920

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150824

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170522

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170426

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170126

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160920

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160720

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150824

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170622